Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Syros Pharmaceuticals, Inc. (SYRS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 01/25/2023 |
SC 13G
| ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 6% stake in Syros Pharmaceuticals, Inc. |
| 09/20/2022 |
SC 13G
| Avidity Partners Management LP reports a 9.9% stake in Syros Pharmaceuticals, Inc. |
| 09/19/2022 |
SC 13G
| Deep Track Capital, LP reports a 10% stake in SYROS PHARMACEUTICALS, INC. |
| 07/08/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/11/2022 |
SC 13G
| Artal International S.C.A. reports a 5.6% stake in Syros Pharmaceuticals, Inc. |
| 12/18/2020 |
SC 13G
| Ally Bridge MedAlpha Master Fund L.P. reports a 5.4% stake in Syros Pharmaceuticals, Inc. |
| 12/14/2020 |
SC 13G
| Bain Capital Life Sciences Fund II, L.P. has filed a Schedule 13D for Syros Pharmaceuticals, Inc. |
| 04/02/2020 |
SC 13G
| Point72 Asset Management, L.P. reports a 5.1% stake in Syros Pharmaceuticals, Inc. |
| 02/07/2020 |
SC 13G
| BlackRock Inc. reports a 6.7% stake in Syros Pharmaceuticals, Inc. |
| 09/09/2019 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 09/06/2019 |
SC 13G
| Nikko Asset Management Americas, Inc. reports a 10.2% stake in Syros Pharmaceuticals, Inc. |
| 04/09/2019 |
SC 13G
| Flynn James E reports a 4.8% stake in Syros Pharmaceuticals, Inc. |
| 02/14/2019 |
SC 13G
| ARK Investment Management LLC reports a 7.3% stake in Syros Pharmaceuticals, Inc. |
| 02/07/2019 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/06/2016 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals |
|
|